Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568692 | 0.85 | DYRK1A (1.00) | DYRK1ARAB9AGSK3BSMN1; SMN2NPC1 | |
| SCHEMBL6068126 | 0.85 | DYRK1A (0.71) | DYRK1ARAB9AGSK3BSMN1; SMN2NPC1 | |
| SCHEMBL6067966 | 0.83 | DYRK1A (0.76) | DYRK1ARAB9AGSK3BSMN1; SMN2NPC1 | |
| SCHEMBL14189669 | 0.81 | RAB9A (0.74) | DYRK1ARAB9AKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL23256894 | 0.80 | DYRK1A (0.64) | DYRK1ARAB9AKMT2AGSK3BSMN1; SMN2 | |
| SCHEMBL22208373 | 0.80 | RAB9A (0.72) | DYRK1ARAB9AKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL17776540 | 0.80 | PDPK1 (0.72) | DYRK1ARAB9AKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL21568049 | 0.80 | DYRK1A (0.76) | DYRK1ARAB9AGSK3BSMN1; SMN2NPC1 | |
| SCHEMBL9893074 | 0.80 | DYRK1A (0.72) | DYRK1ARAB9AKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL21568125 | 0.79 | DYRK1A (0.62) | DYRK1ARAB9AKMT2AGSK3BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | DYRK1A 4090/4885RAB9A 656/4885KMT2A 2426/4885 |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | DYRK1A 4090/4885RAB9A 656/4885KMT2A 2426/4885 |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1S | DYRK1A 4076/4885RAB9A 858/4885KMT2A 2504/4885 |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | DYRK1A 4090/4885RAB9A 656/4885KMT2A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.